SBA preferentially binds to oligosaccharide structures of n-acetylgalactosamine with alpha - or beta - junctions at the end, and to a lesser extent to galactose residues. Binding can be prevented by substitution on the second-to-last sugar, such as the focal point attached to the second-to-last galactose in the type B blood substance.
For research use only, not for clinical use.